AI
| Followers | 843 |
| Posts | 122802 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Thursday, May 11, 2006 5:04:19 PM
COLY CC:
1. PFE plans to run three new phase-2 trials of PF-3512676 in NSCLC, each with 130-140 patients, in combination with : a) Avastin, b) Tarceva, and c) Alimta. Although COLY and PFE are not disclosing the setting or trial designs, my guess is that these trials will test each of the above agents with and without PF-3512676 in second-line NSCLC. PFE also plans a phase-2 trial of PF-3512676 in an undisclosed breast-cancer setting.
2. More Actilon data will be released at DDW later this month.
3. Employees have been directed to work on weekends.
(Just kidding about #3
)
1. PFE plans to run three new phase-2 trials of PF-3512676 in NSCLC, each with 130-140 patients, in combination with : a) Avastin, b) Tarceva, and c) Alimta. Although COLY and PFE are not disclosing the setting or trial designs, my guess is that these trials will test each of the above agents with and without PF-3512676 in second-line NSCLC. PFE also plans a phase-2 trial of PF-3512676 in an undisclosed breast-cancer setting.
2. More Actilon data will be released at DDW later this month.
3. Employees have been directed to work on weekends.
(Just kidding about #3
) “The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
